Sanofi Completes €10 Billion Sale of Opella to CD&R, Transforms into Pure-Play Biopharma
• Sanofi has finalized the sale of a 50% controlling stake in its consumer healthcare business Opella to CD&R, receiving approximately €10 billion in net cash proceeds.
• Opella emerges as the third-largest global player in the OTC and VMS market, with iconic brands like Allegra, Doliprane, and Dulcolax serving over 500 million consumers across 100 countries.
• The transaction marks Sanofi's strategic pivot to become a pure-play biopharma company focused on breakthrough medicines and vaccines, while maintaining a 48.2% stake in Opella.
FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors
• The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment.
• Cobenfy targets muscarinic receptors, unlike traditional antipsychotics that focus on dopamine, potentially reducing side effects like weight gain and movement disorders.
• Clinical trials demonstrated Cobenfy significantly reduced schizophrenia symptoms compared to placebo, marking a transformative moment in managing this challenging condition.
• Expected to launch in late October, Cobenfy offers a new option for adults with schizophrenia, with ongoing studies exploring its potential in Alzheimer's psychosis and other conditions.
© Copyright 2025. All Rights Reserved by MedPath